Ann Arbor, MI Clinical Trials Report — July 2026

Ann Arbor participants should act soon: 51 recruiting trials are expected to close within the next 90 days, including 10 that accept healthy volunteers. The closing studies cover surgery, adolescent health, breast cancer stages, aggression, aging well, opioid analgesics, and advanced solid tumors. Enrollment can end early if a study reaches its target, so people who match these areas should contact research teams now.

Ann Arbor currently has 949 recruiting trials across 219 research facilities. The city opened 9 new studies in July, down from 20 in May and following 12 in June. Despite the slower pace of new openings, the city continues to offer a deep local research network, led by the University of Michigan and its affiliated hospitals.

Closing windows for local participants

The closing-soon list is broad rather than concentrated in one disease area. Surgery accounts for 2 studies. Other conditions and participant groups represented include adolescent health, anatomic stage 0 breast cancer, anatomic stage I breast cancer, anatomic stage IA breast cancer, anatomic stage IB breast cancer, aggression, aging well, opioid-related analgesic research, and advanced solid tumors.

• Surgery (2 trials)
• Adolescent health (1 trial)
• Anatomic stage 0 breast cancer (1 trial)
• Aggression (1 trial)
• Aging well (1 trial)
• Analgesics and opioids (1 trial)
• Advanced solid tumors (1 trial)
• Anatomic stage I, IA, and IB breast cancer categories (1 trial each)

Healthy volunteers have options as well: 10 of the closing-soon studies accept healthy participants, and 86 healthy-volunteer trials are recruiting across Ann Arbor overall. Eligibility may depend on age, medications, medical history, or study-specific screening. People without a diagnosed condition should review these studies promptly, particularly if they can complete visits before enrollment closes.

New studies include a Phase 3 rollover opportunity

July’s new trials include 5 drug studies, 4 device studies, 3 classified as other, 2 behavioral studies, 2 procedures, and 1 combination product. The new-study conditions range from acute myeloid leukemia and myelodysplastic syndrome to chronic low-back pain, cystic fibrosis, depression, gum disease, mood, covert consciousness, and metastatic castration-resistant prostate cancer.

• AstraZeneca’s NCT07691970 is a Phase 3 rollover study for people who completed an earlier clinical study of anifrolumab, marketed as Saphnelo, and benefited from continued treatment. The study plans to enroll 1,072 participants and is designed to provide continued access while monitoring safety and tolerability.
• NCT07705022 is a Phase 2 University of Michigan study involving 60 participants. Researchers are using fMRI during dexmedetomidine and ketamine sedation to study whether mental functions continue at different levels of anesthesia.
• NCT07690657, sponsored by the University of Michigan, is evaluating risk-based and benefit-based algorithms for assigning transition-of-care interventions after hospital discharge. The study plans to include 5,000 participants and will examine unplanned readmission or death within 30 days.
• NCT07685925, the Intern Health Study 2026, is a University of Michigan study of a smartphone intervention for medical interns. It plans to enroll 1,000 participants and focuses on mood, physical activity, and sleep.
• NCT07731750 is a University of Michigan study planning 500 participants. It examines whether personal factors such as symptoms, health history, and lifestyle can help an algorithm identify which pain treatments may work best.
• NCT07696338, the REACT trial, studies early airway-clearance therapies for people with cystic fibrosis. Its two parallel studies examine hypertonic saline and dornase alfa and plan to enroll 405 participants.

The month’s sponsor mix is primarily academic or otherwise categorized rather than industry-led. The University of Michigan sponsors 5 new trials, the University of Michigan Rogel Cancer Center sponsors 2, AstraZeneca sponsors 1, and Nicole Hamblett sponsors 1. Overall, 8 new studies are listed as other-sponsored and 1 as industry-sponsored.

University of Michigan sites provide the broadest access

The University of Michigan is the city’s dominant research hub, with 383 recruiting trials. Its affiliated cancer centers, hospitals, children’s facilities, and health-system locations add substantial capacity across oncology, pediatrics, surgery, neurology, pain, anesthesia, and other specialties.

• University of Michigan (383 trials)
• University of Michigan Rogel Cancer Center (78 trials)
• Trinity Health Saint Joseph Mercy Hospital Ann Arbor (68 trials)
• C S Mott Children’s Hospital (33 trials)
• University of Michigan Comprehensive Cancer Center (32 trials)
• Research Site (25 trials)
• University of Michigan Health System (23 trials)
• VA Ann Arbor Healthcare System (22 trials)
• University of Michigan Hospital (17 trials)
• C.S. Mott Children’s Hospital (16 trials)
• University of Michigan Health and University of Michigan Medical Center (8 trials each)

For cancer research, the Rogel Cancer Center and University of Michigan Comprehensive Cancer Center offer the densest concentration of local options. Families seeking pediatric studies can look first at C S Mott Children’s Hospital locations. Trinity Health Saint Joseph Mercy Hospital and the VA Ann Arbor Healthcare System broaden access for adult and veteran populations.

Eligibility and nearby Michigan alternatives

Two of July’s new studies include children, while 7 include older adults. No new trial is limited exclusively to women or men. Healthy volunteers are not limited to the new-study pipeline: Ann Arbor has 86 recruiting studies accepting healthy participants in total, including 2 of the 9 studies opened this month.

People willing to travel can also search in Detroit, which has 8 recruiting trials, and Grand Rapids, with 5. Southfield and Flint each have 2, while Buckley, Berkeley, Berkley, and Livonia each have 1. These nearby locations may be useful when an Ann Arbor study has restrictive eligibility or closes before an applicant completes screening.

With July’s new-study total below recent months and several local trials approaching their enrollment deadlines, the next step for interested patients and volunteers is to verify eligibility and contact Ann Arbor research sites early. The University of Michigan network remains positioned to add opportunities across both specialty care and healthy-volunteer research as the summer pipeline develops.